The Non-Small Cell Lung Cancer (NSCLC) market was valued at approximately USD 32 billion in 2025 and is projected to grow at a robust CAGR of 8% during the forecast period (2020–2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the NSCLC landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The NSCLC market is increasingly guided by biomarker-driven strategies. EGFR represents a highly lucrative biomarker segment, highlighted by blockbuster treatments like TAGRISSO. Currently, TAGRISSO leads the EGFR inhibitor segment, generating nearly USD 6 billion in annual sales.

Small Cell Lung Cancer (SCLC) accounts for approximately 10–15% of all lung cancer cases, while Non-Small Cell Lung Cancer (NSCLC) represents around 80–85%. In 2024, the United States reported an estimated 204,800 new cases of NSCLC, with around 115,500 cases in men and 89,300 cases in women. Age plays a significant role in NSCLC prevalence, with individuals aged 65 and older being more affected than those under 65. In 2024, approximately 140,000 NSCLC cases in the U.S. occurred in patients aged 65 and above.

KRAS NSCLC primarily includes two subtypes: KRAS G12C and KRAS non-G12C (such as G12V, G12D, G13D, G12R, and others). In Japan in 2024, approximately 4,900 cases were KRAS G12C, while around 13,300 cases were KRAS non-G12C.

DelveInsight’s report, “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Non-Small Cell Lung Cancer (NSCLC) landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines NSCLC market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Small Cell Lung Cancer Market Forecast

Some of the key facts of the Non-Small Cell Lung Cancer Market Report:

• Key Non-Small Cell Lung Cancer Companies: AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan Oncology/ Taiho Pharma, Genentech/Roche, Betta Pharma/ Xcovery, Pfizer, Takeda Pharmaceuticals, AstraZeneca, Janssen, Boehringer Ingelheim, Pfizer, Merck, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, AstraZeneca, Bristol-Myers Squibb, AstraZeneca/ Daiichi Sankyo, Amgen, Blueprint Medicines/Rigel Pharmaceuticals, and others

• Key Non-Small Cell Lung Cancer Therapies: KEYTRUDA (pembrolizumab), Telisotuzumab vedotin, Datopotamab deruxtecan (Dato-DXd), Serplulimab (HLX10), V940 (mRNA-4157) + Pembrolizumab, Plinabulin + Docetaxel, Zipalertinib, TECENTRIQ (atezolizumab), ENSACOVE (ensartinib), BRAFTOVI + MEKTOVI, ALUNBRIG, TAGRISSO (osimertinib), RYBREVANT (amivantamab), GILOTRIF/GIOTRIF (afatinib maleate), VIZIMPRO (dacomitinib), KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), TECENTRIQ (atezolizumab), IMFINZI (durvalumab), AUGTYRO (repotrectinib), ENHERTU (trastuzumab deruxtecan), LUMAKRAS/ LUMYKRAS (sotorasib), GAVRETO (pralsetinib), and others

• The Non-Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Small Cell Lung Cancer pipeline products will significantly revolutionize the Non-Small Cell Lung Cancer market dynamics.

Non-Small Cell Lung Cancer Overview

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 80–85% of all lung cancer cases. It grows and spreads more slowly than Small Cell Lung Cancer (SCLC) and includes subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC is often diagnosed at an advanced stage and may be driven by genetic mutations, making targeted therapies and immunotherapies important treatment options. Risk factors include smoking, environmental exposures, and genetic predisposition. Early detection and personalized treatment approaches improve patient outcomes.

Get a Free sample for the Non-Small Cell Lung Cancer Market Report:

https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market

Key Trends in Non-Small Cell Lung Cancer Therapeutics Market:

• Rising Adoption of Targeted Therapies: Increasing use of EGFR, ALK, and ROS1 inhibitors for mutation-driven NSCLC.

• Immunotherapy Expansion: Growing uptake of PD-1/PD-L1 and CTLA-4 inhibitors as first-line and combination treatments.

• Precision Medicine & Biomarker Testing: Enhanced molecular diagnostics enabling personalized treatment strategies.

• Pipeline Innovation: Development of next-generation TKIs, bispecific antibodies, and combination therapies to overcome resistance.

• Market Growth in Emerging Regions: Rising NSCLC prevalence and improved healthcare infrastructure in Asia-Pacific and Latin America.

• Digital Health Integration: Use of AI, telemedicine, and remote monitoring to optimize treatment and patient outcomes.

Non-Small Cell Lung Cancer Epidemiology

The report on Non-Small Cell Lung Cancer (NSCLC) epidemiology provides a comprehensive analysis of the disease’s prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on key genetic subtypes such as EGFR and KRAS mutations. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of NSCLC and plan targeted interventions, research, and treatment strategies.

Non-Small Cell Lung Cancer Epidemiology Segmentation:

The Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Non-Small Cell Lung Cancer

• Prevalent Cases of Non-Small Cell Lung Cancer by severity

• Gender-specific Prevalence of Non-Small Cell Lung Cancer

• Diagnosed Cases of Episodic and Chronic Non-Small Cell Lung Cancer

Download the report to understand which factors are driving Non-Small Cell Lung Cancer epidemiology trends @ Non-Small Cell Lung Cancer Epidemiology Forecast

Recent Development In The NSCLC Treatment Landscape:

• In September 2025, Results from a multinational Phase 2 clinical trial support the potential of sunvozertinib as an effective treatment for patients with previously treated non–small cell lung cancer (NSCLC) harboring specific EGFR mutations. EGFR exon 20 insertion mutations, which account for approximately 12% of all EGFR-mutated NSCLC cases, are typically resistant to most tyrosine kinase inhibitors (TKIs). The findings suggest that sunvozertinib could offer a valuable treatment option for patients with advanced NSCLC who have received prior platinum-based chemotherapy.

• In September 2025, Data from the Phase 3 FLAURA2 trial (NCT04035486), presented at the 2025 World Conference on Lung Cancer, revealed that combining osimertinib (Tagrisso) with chemotherapy as a first-line therapy led to a statistically significant and clinically meaningful improvement in overall survival (OS) compared to osimertinib alone in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC).

• In September 2025, Sun-Min Lim, MD, PhD, an associate professor at Severance Hospital, Yonsei University Health System, highlighted the potential of subcutaneous amivantamab-vmjw (Rybrevant) as a first-line treatment for advanced EGFR-mutant non–small cell lung cancer (NSCLC), based on data from the Phase 2 PALOMA-2 study (NCT05498428). The study assessed subcutaneous amivantamab combined with chemotherapy in patients with advanced NSCLC harboring EGFR exon 20 insertion mutations. Results presented at the 2025 IASLC World Conference on Lung Cancer demonstrated that the subcutaneous formulation achieved comparable response rates, duration of response, and survival outcomes to the intravenous version evaluated in the Phase 3 PAPILLION trial (NCT04538664).

• In September 2025, Huons expanded its drug portfolio by adding a targeted therapy for non-small cell lung cancer (NSCLC) and is enhancing its drug development pipeline through open innovation. The company announced an agreement with Therapex to in-license TRX-211, a preclinical NSCLC-targeted anticancer candidate, at Huons’ Dong-Am Research Center. Under the deal, Huons will lead clinical trial development for TRX-211 and holds the option to acquire global rights in the future. TRX-211 is an oral tyrosine kinase inhibitor (TKI) designed for EGFR exon 20 insertion-mutant NSCLC. Therapex shared preclinical data demonstrating the drug’s improved efficacy and selectivity at the AACR Annual Meeting 2024.

• In August 2025, TOLREMO Therapeutics announced that its lead drug candidate, TT125-802, has been granted two FDA Fast Track designations for the treatment of non-small cell lung cancer (NSCLC).

• In August 2025, Innovent Biologics has obtained FDA approval to initiate a global Phase 3 trial (MarsLight-11) of IBI363, a novel PD-1/IL-2α-bias bispecific antibody, targeting immunotherapy-resistant squamous NSCLC, representing the company’s first global pivotal study.

• In August 2025, SystImmune and Bristol Myers Squibb announced that the FDA has granted Breakthrough Therapy Designation to izalontamab brengitecan (iza-bren) for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R mutations, following disease progression on EGFR tyrosine kinase inhibitors and platinum-based chemotherapy.

• In July 2025, Thermo Fisher Scientific announced that the FDA has approved the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Sequencer as a companion diagnostic for Dizal’s ZEGFROVY® (sunvozertinib) to identify EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The test also enables profiling of 46 genes, providing rapid genomic insights in approximately 24 hours, supporting precision oncology and informed treatment decisions in clinical practice.

• In March 2025, Johnson & Johnson (NYSE: JNJ) announced Phase 3 MARIPOSA study results showing that RYBREVANT® (amivantamab-vmjw) combined with LAZCLUZE™ (lazertinib) significantly improved overall survival (OS) compared to osimertinib. This head-to-head trial in first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletions or L858R mutations revealed a median OS exceeding one year beyond the three-year median seen with osimertinib, and the median OS has not yet been reached. This marks the first study demonstrating a statistically significant, clinically meaningful OS benefit over osimertinib.

• In February 2025, MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical firm specializing in targeted cancer immunotherapies, has shared encouraging updated results from its key Phase 2 THIO-101 trial. This study is assessing its main drug candidate, THIO, given sequentially with Regeneron’s immune checkpoint inhibitor cemiplimab (Libtayo®), in patients with advanced non-small cell lung cancer (NSCLC) who have failed two or more previous standard therapies.

• In January 2025, The U.S. Food and Drug Administration (FDA) has granted priority review to Dizal’s new drug application (NDA) for Sunvozertinib, intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

• In December 2024, The FDA awarded breakthrough therapy designation to sacituzumab tirumotecan (MK-2870/SKB264) for treating patients with advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC).

• In December 2024, Incyte (Nasdaq: INCY) shared the results from the Phase 3 POD1UM-304 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy for treating adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer (NSCLC) without a driver mutation. These findings were presented today in a mini oral session at the European Society for Medical Oncology (ESMO) Asia Congress 2024, held in Singapore and virtually.

• In December 2024, Nuvation Bio Inc., a global biopharmaceutical company dedicated to addressing unmet oncology needs, announced that the U.S. FDA has accepted its New Drug Application (NDA) for taletrectinib. This investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) is being assessed for the treatment of advanced ROS1-positive non-small cell lung cancer (NSCLC), regardless of prior treatment history.

• In December 2024, Merus N.V. announced that the FDA has approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatment for adults with advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) with a neuregulin 1 (NRG1) gene fusion, following disease progression after prior systemic therapy.

Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Small Cell Lung Cancer Therapies and Key Companies

• Telisotuzumab vedotin: AbbVie

• Datopotamab deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo

• Serplulimab (HLX10): Shanghai Henlius Biotech

• V940 (mRNA-4157) + Pembrolizumab: Moderna Therapeutics/ Merck

• Plinabulin + Docetaxel: BeyondSpring

• Zipalertinib: Cullinan Oncology/ Taiho Pharma

• TECENTRIQ (atezolizumab): Genentech/Roche

• ENSACOVE (ensartinib): Betta Pharma/ Xcovery

• BRAFTOVI + MEKTOVI: Pfizer

• ALUNBRIG: Takeda Pharmaceuticals

• TAGRISSO (osimertinib): AstraZeneca

• RYBREVANT (amivantamab): Janssen

• GILOTRIF/GIOTRIF (afatinib maleate): Boehringer Ingelheim

• VIZIMPRO (dacomitinib): Pfizer

• KEYTRUDA (pembrolizumab): Merck

• OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceutical

• TECENTRIQ (atezolizumab): Genentech/ Hoffmann-La Roche

• IMFINZI (durvalumab): AstraZeneca

• AUGTYRO (repotrectinib): Bristol-Myers Squibb

• ENHERTU (trastuzumab deruxtecan): AstraZeneca/ Daiichi Sankyo

• LUMAKRAS/ LUMYKRAS (sotorasib): Amgen

• GAVRETO (pralsetinib): Blueprint Medicines/Rigel Pharmaceuticals

To know more about Non-Small Cell Lung Cancer companies working in the treatment market, visit @ Non-Small Cell Lung Cancer Clinical Trials and Therapeutic Assessment

Non-Small Cell Lung Cancer Market Drivers

• Increasing prevalence of NSCLC globally, driving demand for effective therapies

• Growth of targeted therapies and immunotherapies for mutation-specific NSCLC subtypes (EGFR, ALK, KRAS)

• Advancements in molecular diagnostics and biomarker testing enabling precision medicine

• Rising healthcare expenditure and government initiatives supporting cancer care

• Expanding awareness and early diagnosis through screening programs

• Development of combination therapies improving patient outcomes and survival rates

Non-Small Cell Lung Cancer Market Barriers

• High cost of targeted therapies and immunotherapies limiting patient access

• Complex clinical trial designs and lengthy regulatory approval processes

• Resistance development to existing treatments reducing long-term efficacy

• Limited awareness and accessibility in emerging markets

• Side effects and safety concerns associated with advanced therapies

• Variability in patient response due to genetic and environmental factors

Scope of the Non-Small Cell Lung Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Non-Small Cell Lung Cancer Companies: AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan Oncology/ Taiho Pharma, Genentech/Roche, Betta Pharma/ Xcovery, Pfizer, Takeda Pharmaceuticals, AstraZeneca, Janssen, Boehringer Ingelheim, Pfizer, Merck, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, AstraZeneca, Bristol-Myers Squibb, AstraZeneca/ Daiichi Sankyo, Amgen, Blueprint Medicines/Rigel Pharmaceuticals, and others

• Key Non-Small Cell Lung Cancer Therapies: KEYTRUDA (pembrolizumab), Telisotuzumab vedotin, Datopotamab deruxtecan (Dato-DXd), Serplulimab (HLX10), V940 (mRNA-4157) + Pembrolizumab, Plinabulin + Docetaxel, Zipalertinib, TECENTRIQ (atezolizumab), ENSACOVE (ensartinib), BRAFTOVI + MEKTOVI, ALUNBRIG, TAGRISSO (osimertinib), RYBREVANT (amivantamab), GILOTRIF/GIOTRIF (afatinib maleate), VIZIMPRO (dacomitinib), KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), TECENTRIQ (atezolizumab), IMFINZI (durvalumab), AUGTYRO (repotrectinib), ENHERTU (trastuzumab deruxtecan), LUMAKRAS/ LUMYKRAS (sotorasib), GAVRETO (pralsetinib), and others

• Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies

• Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Non-Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Non-Small Cell Lung Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Non-Small Cell Lung Cancer market share @ Non-Small Cell Lung Cancer Treatment Market

Table of Contents

1. Non-Small Cell Lung Cancer Market Report Introduction

2. Executive Summary for Non-Small Cell Lung Cancer

3. SWOT analysis of Non-Small Cell Lung Cancer

4. Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance

5. Non-Small Cell Lung Cancer Market Overview at a Glance

6. Non-Small Cell Lung Cancer Disease Background and Overview

7. Non-Small Cell Lung Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Small Cell Lung Cancer

9. Non-Small Cell Lung Cancer Current Treatment and Medical Practices

10. Non-Small Cell Lung Cancer Unmet Needs

11. Non-Small Cell Lung Cancer Emerging Therapies

12. Non-Small Cell Lung Cancer Market Outlook

13. Country-Wise Non-Small Cell Lung Cancer Market Analysis (2020–2034)

14. Non-Small Cell Lung Cancer Market Access and Reimbursement of Therapies

15. Non-Small Cell Lung Cancer Market Drivers

16. Non-Small Cell Lung Cancer Market Barriers

17. Non-Small Cell Lung Cancer Appendix

18. Non-Small Cell Lung Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/